Skip to main content

Table 1 Pharmacotherapy

From: Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experience

MEDICATION

DOSAGE

ON- OR

OFF-LABEL?

NUMBER OF SUBJECTS (% OF TOTAL)

PARTIAL USE (NUMBER OF SUBJECTS)

LIRAGLUTIDE

1.8 mg daily

Off-label (during the study period)

On-label (2016 Nov)

39 (90.7%)

1 < 6 months

1 6–11 months

SGLT2 INHIBITORS

Canagliflozin 300 mg daily

Dapagliflozin 10 mg daily

Off-label

37 (86.0%)

5 < 6 months

ORLISTAT

120 mg B.I.D.

On-label

34 (79.1%)

4 < 6 months

3 6–11 months

METFORMIN

2000 mg daily

Off-label

28 (65.1%)

2 < 6 months

BUPROPION +

NALTREXONE

300 mg + 32 mg daily

On-label (USA)

Off-label (Brazil)

25 (58.1%)

2 < 6 months

10 6–11 months

SIBUTRAMINE

10-15 mg daily

On-label (Brazil)

Prohibited (USA)

23 (53.5%)

3 < 6 months

TOPIRAMATE

100 mg daily

On-label (USA)

(when combined with phentermine)

Off-label (Brazil)

13 (30.2%)

4 < 6 months

TESTOSTERONE

1000 mg I.M. every 3 months

On-label

(when hypogonadism is present)

12 (27.9%)

-

FLUOXETINE

20-60 mg daily

Off-label

11 (25.6%)

1 < 6 months

SERTRALINE

50-200 mg daily

Off-label

10 (23.3%)

1 < 6 months